Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with ...

All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and ...

to Neutral from Underperform with an unchanged price target of $3 after a case study report for the first active lupus nephritis patient dosed with FT819 in the autoimmune phase 1 study ...

Fate Therapeutics, Inc. (NASDAQ:FATE) recently reported positive data from its phase 1 autoimmunity study using FT819 for the treatment of patients with moderate-to-severe Systemic Lupus ...

Fate Therapeutics (FATE) presented new clinical and translational data from the company’s FT819 Phase 1 Autoimmunity study for ...

The company said the patient, an African American-Asian woman diagnosed with lupus nephritis, received fludarabine-free conditioning followed by a single dose of FT819. The woman achieved clinical ...

After Fate Therapeutics (FATE) presented initial clinical and translational data from the first patient treated in its FT819 Phase 1 Autoimmunity study for lupus nephritis, or LN, Stifel says the ...

The change comes as the company reaffirms its commitment to developing new off-the-shelf cellular immunotherapies.